NUR 123 Study Hub
Sections
Med-Surg · ATI / NCLEX focused

Oxygenation Study Guide

COPD, asthma, pneumonia, respiratory assessment, oxygen devices, ABGs, acid-base balance, priorities, delegation, PERSON care planning, and medications - organized for fast clinical reasoning.

16 objectives18 required terms + FEV1/FVC12 medication/vaccine classes
Quick note

Separate the diseases

Asthma = variable/reversible narrowing. COPD = persistent obstruction. Pneumonia = inflammatory alveolar fluid/exudate causing gas-exchange failure.

Quick note

Silent chest = emergency

Less wheezing is not improvement when airflow is critically low. Silent chest, exhaustion, falling LOC, or inability to speak are red flags.

Quick note

ABG algorithm

Always use the same order: pH → PaCO2 → HCO3 → compensation → PaO2.

Quick note

Rescue vs controller

SABA = rapid rescue. ICS/LABA/LAMA/leukotriene/biologic therapies are maintenance unless the prescribed asthma plan specifically says otherwise.

How this guide is organized

This page is built from the supplied Completed Oxygenation Study Guide. The professor's Oxygenation Lectures Parts 1 and 2 remain the primary course source, with only the study guide's labeled supplements used to fill objective gaps.

LectureCourse lecture content is presented first.
Web supplementAdded when the Unit 7 objective asks for material not fully covered in lecture.
Course sourceUsed for the NUR 121 PERSON framework in Objective 10.
Current practiceFlags a meaningful difference between course wording and current guidance.
No objective matches that search.
Objective 1

Compare etiology and pathophysiology of COPD, asthma, and pneumonia

LectureWeb supplementLecture: L1 pp. 8-10, 35; L2 pp. 4, 28-31. Web: [W1-W5].

The fastest way to separate the disorders is to ask what is physically blocking airflow or gas exchange: narrowed inflamed airways in asthma, persistent airflow obstruction from mucus/alveolar destruction in COPD, or inflammatory fluid/exudate in pneumonia.

ConditionEtiology / triggerCore pathophysiologyNCLEX recognition cue
Chronic bronchitis (COPD)Smoking is the major lecture risk; also occupational fumes/dust, air pollution, infection/aging, genetics.Chronic bronchial inflammation + excess thick mucus narrow airways and impair clearance. Uneven ventilation causes V/Q mismatch; hypoxemia and CO2 retention can develop.Chronic cough + sputum + dyspnea; coarse crackles/mucus; persistent obstruction.
Emphysema (COPD)Usually smoking/exposure; alpha-1 antitrypsin deficiency is an inherited cause.Alveolar walls are destroyed and elastic recoil is lost. Small airways collapse on exhalation → air trapping/hyperinflation and reduced gas-exchange surface area.Hyperinflation/barrel chest + diminished breath sounds + prolonged exhalation/air trapping.
AsthmaAtopy/allergens; exercise, stress, heat/cold, infections; late-onset and obesity phenotypes can occur.Chronic airway inflammation with episodic bronchoconstriction, mucosal edema, and mucus. Airflow limitation is characteristically variable and usually reversible.Episodic wheeze/cough/chest tightness, prolonged expiration, trigger pattern, variable/reversible airflow.
PneumoniaAcute lung infection, usually microorganisms; lecture categories include CAP, HAP/VAP, HCAP, opportunistic; aspiration can also cause pneumonia.Inflammatory edema/exudate fills alveoli/interstitium. Poorly ventilated alveoli remain perfused → low V/Q or shunt-like physiology → hypoxemia.Fever/chills + cough/sputum + crackles/pleuritic pain + new infiltrate/oxygenation decline.
High-yield distinction: Asthma is usually variable/reversible. COPD is persistent airflow limitation. Pneumonia is primarily an infectious/inflammatory gas-exchange problem rather than a chronic obstructive disease.
Objective 2

Risk factors and at-risk populations

LectureWeb supplementLecture: L2 pp. 6, 31; L1 pneumonia section. Web: [W1-W6].
ConditionLecture risksWeb completion / at-risk groups
COPDSmoking; occupational chemicals/fumes/dust; air pollution; infection; aging; genetics; AAT deficiency.Long cumulative inhalational exposure; secondhand smoke/combustion exposure. Consider AAT deficiency when COPD is unusually early/severe or occurs with limited smoking exposure.
AsthmaAtopy; allergens; exercise; stress; heat/cold; respiratory infections; adult onset; obesity phenotype.Family/personal allergic disease, occupational sensitizers/irritants, and tobacco/vape exposure may increase risk or worsen control. Normal IgE/eosinophils do not exclude asthma.
PneumoniaOpportunistic pneumonia in immunocompromised patients; aspiration precautions emphasized.Older adults; chronic lung/heart/liver disease or diabetes; smoking; excessive alcohol; immunocompromise; dysphagia/decreased LOC; recent hospitalization/ventilation for HAP/VAP risk.
Assessment cue: A risk factor does not equal a diagnosis. Pair exposure history with symptoms, examination findings, and objective testing.
Objective 3

Acute and chronic assessment findings

LectureWeb supplementLecture: L1 pp. 12-13, 36; L2 pp. 8, 14, 33-35, 39. Web clarifies severity cues.

Baseline respiratory assessment anchors

What to assessLecture anchorWhy it matters
Respiratory rate / patternNormal adult RR 12-20; bradypnea <12; tachypnea >20; assess depth and effort.Trend is often more useful than one value; increasing work of breathing can precede a major SpO2 drop.
Breath soundsCrackles/rales, rhonchi, wheezing, stridor; note diminished/absent areas.Wheeze = narrowed airway; rhonchi/coarse sounds = secretions; crackles = fluid/opening small airways; stridor = upper-airway emergency.
OxygenationPulse oximetry, ABG/VBG; assess dyspnea, accessory muscles, cyanosis.SpO2 is a screening measure; ABG directly evaluates PaO2/PaCO2 and acid-base status.
Cough / sputum / painCharacter, amount/color of sputum; pleuritic pain; hemoptysis.Change from baseline may signal infection or exacerbation.

Disease patterns

ConditionChronic / common findingsAcute deterioration cues
COPDDyspnea, chronic cough/sputum; diminished sounds or coarse crackles; hyperinflation, barrel chest, hyperresonance, retractions; hypoxemia/cyanosis; polycythemia can occur.More dyspnea/sputum, new mental-status change, worsening ABG, respiratory failure; infection/environmental irritants are common triggers.
AsthmaVariable cough/wheeze/chest tightness; prolonged expiration, air trapping/hyperinflation; night symptoms may occur.Tachypnea/tachycardia, orthopnea, accessory muscles, diaphoresis, inability to speak full sentences, worsening hypoxemia. Silent chest is an ominous sign of minimal airflow.
PneumoniaCough with sputum, dyspnea, pleuritic chest pain, fever/chills, fatigue; crackles and hypoxemia are common.Hypotension, tachycardia, severe hypoxemia, new confusion, increasing work of breathing, sepsis or respiratory failure.
Priority cue: Do not be reassured by less wheezing in a patient whose asthma is worsening. If airflow becomes critically low, the chest may become quiet or silent.
Objective 4

Diagnostic tests and expected results

LectureWeb supplementCurrent practiceLecture: L1 pp. 19-23, 38; L2 pp. 9, 36-38. Web: [W1-W5, W9-W10].
TestCOPDAsthmaPneumonia / nursing note
Spirometry / PFTLecture: FVC, FEV1, FEV1/FVC. Current GOLD confirms COPD with post-bronchodilator FEV1/FVC <0.70. Lecture airflow grades: FEV1 ≥80%, 50-79%, 30-49%, <30%.Looks for variable expiratory airflow and bronchodilator response. PEF can be used when spirometry is unavailable or for monitoring.Not the primary diagnostic test for acute pneumonia; may be deferred during acute illness.
Chest x-rayMay show hyperinflation; also helps evaluate other causes/complications.Often normal between attacks; useful when another diagnosis/complication is suspected.Commonly shows a new infiltrate/consolidation when clinical pneumonia is present.
CT chestCan define emphysema, bullae, alternative diagnoses/complications when ordered.Selected cases, not routine uncomplicated asthma.Selected severe/complicated or unclear cases; can define abscess/effusion.
ABGMay show hypoxemia/hypercapnia. Lecture COPD example: low pH, high PaCO2, high HCO3, low PaO2 = partially compensated respiratory acidosis.Used in severe exacerbation/respiratory failure, not routine stable asthma.Assesses oxygenation/ventilation in severe illness.
AAT levelDetects alpha-1 antitrypsin deficiency.Not diagnostic for asthma.Not a routine pneumonia test.
IgE / eosinophils / skin testingNot diagnostic for COPD.Supports allergic/Type 2 phenotype; normal values do not rule asthma out.Not routine pneumonia testing.
Sputum / blood culturesObtained when infection is suspected and severity/context warrants.Not routine unless infection is being evaluated.Lecture includes sputum specimens and blood cultures; obtain before antibiotics when ordered and when it will not delay urgent therapy.
BronchoscopySelected diagnostic/therapeutic use.Selected use.Lecture lists bronchoscopy; useful for airway sampling/obstruction or complicated cases.
V/Q scanNot a COPD diagnostic test; evaluates ventilation vs perfusion when PE is suspected.May be used when PE is a competing diagnosis, not routine asthma.Not routine pneumonia; can help evaluate PE in appropriate patients.
Current GOLD correction: The lecture emphasizes FEV1/FVC <70%. Modern GOLD specifies post-bronchodilator FEV1/FVC <0.70 for confirmation. FEV1 grade describes airflow obstruction, but current treatment decisions also consider symptoms and exacerbation history. [W1]
Current pneumonia terminology: The lecture lists HCAP. Current ATS/IDSA guidance no longer treats HCAP as a separate category; resistant-organism risk is assessed using specific clinical risk factors. Keep “HCAP” recognizable for course questions. [W4]
Objective 5

Management recommendations and nursing interventions

LectureWeb supplementCurrent practiceLecture: L1 pp. 38-39; L2 pp. 10-26, 40-49. Web: [W1-W7, W26].

COPD management

  • Smoking cessation is the most important modifiable lecture priority; nicotine replacement/counseling may help.
  • Use short- and long-acting bronchodilators, anticholinergics, selected inhaled corticosteroid therapy, and combination inhalers according to symptoms/exacerbations.
  • Oxygen: lecture goal SaO2 >90%. In acute COPD at risk for hypercapnia, titrate to the ordered target and reassess ABGs - do not withhold needed oxygen because of “hypoxic drive.”
  • Pursed-lip breathing, huff coughing, chest physiotherapy when indicated, hydration if appropriate, expectorants as ordered.
  • Pulmonary rehab, exercise/education, nutrition to maintain body weight and meet metabolic needs.
  • Selected surgery: bullectomy, lung-volume reduction, lung transplantation.

Asthma management

  • Written asthma action plan, trigger control, adherence, and correct inhaler technique.
  • Lecture PEF zones: Green 80-100%, Yellow 50-79%, Red <50% of personal best.
  • SABA (albuterol/levalbuterol) = rapid bronchodilation; ICS = anti-inflammatory controller; salmeterol = maintenance, not rescue and not asthma monotherapy.
  • Leukotriene drugs and anti-IgE biologic therapy are controller options in selected patients.
  • Current GINA: SABA-only treatment is no longer recommended for adults/adolescents; use an ICS-containing strategy according to the prescribed plan. [W2]

Pneumonia management

  • Give antibiotics on time when bacterial pneumonia is treated; do not delay urgent therapy in an unstable patient.
  • Oxygen/respiratory treatments, airway protection, secretion mobilization, chest physiotherapy when indicated.
  • Hydration, nutrition, rest balanced with activity, analgesics/antipyretics, pleuritic-pain management.
  • Aspiration prevention: assess swallowing/LOC, safe meal positioning, SLP/diet recommendations, oral hygiene and feeding precautions.
  • Health promotion: hand hygiene, smoking cessation, vaccination.

Oxygen-delivery quick guide

DeviceTypical web-supplement rangeNursing / exam cue
Nasal cannula1-6 L/min; about 24-44% FiO2Comfortable; patient can eat/talk. Humidification may be needed with higher/prolonged flow per policy.
Simple mask6-10 L/min; about 28-50% FiO2Do not run below device minimum because CO2 rebreathing can occur.
Venturi maskAdapter sets a precise FiO2, commonly ~24-60%Useful when controlled oxygen concentration is important; do not change adapter/flow arbitrarily.
Non-rebreather10-15 L/min; about 60-80% FiO2High concentration for a spontaneously breathing patient. Keep reservoir bag partially inflated.
HFNCUp to ~60 L/min; FiO2 independently adjustable up to high concentrationsHeated/humidified high flow; decreases work of breathing and can improve oxygenation.
CPAPOne continuous positive airway pressureKeeps airways/alveoli open; patient must be breathing spontaneously.
BiPAPHigher inspiratory + lower expiratory pressureProvides pressure support plus PEEP-like expiratory pressure; useful in selected ventilatory failure.
Device note: These ranges are from the study guide’s NCBI Nursing Skills supplement. Follow the ordered device setting and facility policy. [W26]
Objective 6

Acute and chronic complications: cause, prevention, and management

LectureWeb supplementLecture: L1 p. 37; L2 pp. 14, 39, 48. Web fills prevention/response.
ComplicationCause / recognitionPrevention / management focus
Status asthmaticusSevere asthma exacerbation with escalating obstruction; tachypnea, hypoxemia, accessory muscles, inability to speak; silent chest can occur.Emergency: oxygen, repeated/continuous inhaled SABA, ipratropium, systemic corticosteroid; IV fluids as ordered; prepare for intubation/ventilation if failing.
COPD respiratory failureExacerbation/infection can worsen V/Q mismatch and CO2 retention; mental-status change and worsening ABG are danger signs.Titrate oxygen to ordered target, bronchodilators, treat trigger, airway clearance, ABG monitoring; NIV (BiPAP) or invasive ventilation when indicated.
Pulmonary hypertension / cor pulmonaleChronic hypoxemia raises pulmonary vascular resistance → right-heart strain/failure.Prevent/treat chronic hypoxemia as prescribed; manage COPD; watch edema/JVD/weight; coordinate cardiopulmonary care.
PneumothoraxBullae may rupture; severe lung disease increases risk. Sudden dyspnea/pleuritic pain with unilateral decreased sounds is concerning.Urgent assessment, oxygen/support, imaging; chest tube/other intervention as ordered. Escalate immediately if unstable.
Pneumonia / recurrent infectionImpaired clearance and COPD increase infection risk.Vaccination, smoking cessation, hand hygiene, early evaluation/treatment.
Pleural effusion / pleurisy / lung abscessPneumonia can extend to pleural space or form localized infection.Antimicrobial therapy and drainage/procedures when ordered; monitor pain, breath sounds, oxygenation and sepsis.
ARDSSevere inflammatory lung injury from pneumonia/sepsis can cause refractory hypoxemia.Rapid critical-care escalation; lung-protective ventilation/oxygenation strategy per team.
SepsisInfection with organ dysfunction: hypotension, altered mentation, poor perfusion, rising O2 need.Recognize early; cultures/lactate per protocol; prompt antimicrobials and fluids/vasopressors as ordered; monitor perfusion/urine output.
Objective 7

End-of-life issues in end-stage lung disease

Web supplementThis objective is not directly developed in the lecture. Current COPD guidance: [W1].

Goals and planning

  • Introduce palliative care based on symptom burden and goals, not only in the final days. It can be provided alongside disease-directed treatment.
  • Discuss advance directives, health-care proxy/surrogate, code status, hospitalization preferences, and preferences for NIV, intubation/mechanical ventilation, and place of care/death before a crisis.
  • A severe COPD exacerbation admission can be a useful trigger for advance-care planning because prognosis is variable.

Comfort and support

  • Address refractory dyspnea, anxiety, fatigue, insomnia, pain, and secretion burden.
  • Nonpharmacologic dyspnea measures include positioning, fan/cool air, pacing, and breathing techniques; medications are individualized by the palliative/medical team.
  • Hospice is appropriate when goals shift to comfort and eligibility criteria are met; involve family/caregivers and social work/case management.
NCLEX ethics cue: A competent patient may choose or refuse life-sustaining treatment. The nurse clarifies goals, ensures informed communication, treats distress, and advocates for care consistent with the patient’s wishes.
Objective 8

Interpret ABGs for oxygenation and acid-base balance

LectureWeb supplementLecture: L1 pp. 22-33; L2 p. 37. Web: [W8-W10].

Course ABG anchors

ComponentLecture normalWhat it tells you
pH7.35-7.45Overall acidemia (<7.35) or alkalemia (>7.45).
PaCO235-45 mmHgRespiratory component. CO2 is an acid: high CO2 → acid direction; low CO2 → base direction.
HCO3-22-26 mEq/LMetabolic/renal component. High HCO3 → base direction; low HCO3 → acid direction.
PaO280-100 mmHgArterial oxygenation. Lecture hypoxemia scale is listed below; laboratory ranges vary.
Course-specific hypoxemia scale: mild SpO2 90-94% / PaO2 60-79; moderate SpO2 75-89% / PaO2 40-59; severe SpO2 <75% / PaO2 <40. Use these values when the course asks for the lecture scale; clinical thresholds and pulse-ox accuracy vary by context. [L1 p.13; W9-W10]

Four-step NCLEX method

1
pH<7.35 = acid; >7.45 = base; 7.35-7.45 = normal / possibly fully compensated.
2
PaCO2>45 points respiratory acid; <35 points respiratory base.
3
HCO3-<22 points metabolic acid; >26 points metabolic base.
4
Match + compensateMatch pH with the primary abnormality, then assess compensation and PaO2.

Compensation shorthand used on nursing exams

PatternpHPaCO2 / HCO3Interpretation
UncompensatedAbnormalPrimary value abnormal; the other system is still near normal.No meaningful compensation yet.
Partially compensatedStill abnormalBoth PaCO2 and HCO3 are abnormal in opposite physiologic directions.Compensation has begun but pH is not normal.
Fully compensated7.35-7.45Both PaCO2 and HCO3 are abnormal.Use which side of 7.40 the pH lies on plus clinical context to identify the original process; mixed disorders are possible.

Practice patterns

ABGInterpretationWhy
7.30 / 52 / 24 / PaO2 65Uncompensated respiratory acidosis + hypoxemiapH acid, CO2 acid, HCO3 normal.
7.32 / 55 / 29Partially compensated respiratory acidosispH still acid; high CO2 primary; high HCO3 compensating.
7.37 / 52 / 30Fully compensated respiratory acidosis (exam shorthand)pH normal but on acid side; CO2 high, HCO3 high.
7.48 / 30 / 24Uncompensated respiratory alkalosispH base, CO2 base, HCO3 normal.
7.28 / 30 / 16Partially compensated metabolic acidosispH acid; HCO3 low primary; CO2 low compensation.
7.48 / 48 / 32Partially compensated metabolic alkalosispH base; HCO3 high primary; CO2 high compensation.
Objective 9

Causes and manifestations of common acid-base imbalances

LectureWeb supplementLecture: L1 pp. 26-33. Web: [W8].
DisorderLecture causesCommon manifestations / compensation
Respiratory acidosis“DEPRESS”: Drugs, Edema, Pneumonia, Respiratory-center damage, Emboli, bronchial Spasms/asthma, Sac elasticity damage/COPD-emphysema. Also anesthesia/drug overdose, atelectasis.Hypoventilation, dyspnea, headache, drowsiness/confusion, weakness, low BP, dysrhythmias; hyperkalemia may occur. Kidneys retain HCO3/excrete acid over time.
Respiratory alkalosisHyperventilation, increased temperature, salicylate toxicity, extreme anxiety, pulmonary embolus/fear, excessive mechanical ventilation; lecture also lists gram-negative bacteria.Deep rapid breathing, lightheadedness, tingling/numbness, tachycardia, confusion, nausea, seizures if severe; hypokalemia can occur. Kidneys lower HCO3 over time.
Metabolic acidosisDKA, acute/chronic kidney injury, malnutrition, severe diarrhea; increased acid production or loss of HCO3.Kussmaul/compensatory hyperventilation, headache, warm/flushed skin, hypotension, N/V, confusion/drowsiness, hyperkalemia. Lungs blow off CO2.
Metabolic alkalosisExcess vomiting/gastric suction, diuretics/volume depletion, excessive antacid/NaHCO3, hyperaldosteronism.Compensatory hypoventilation, restlessness then lethargy/confusion, dysrhythmias, tremor/cramps/tingling, hypokalemia. Lungs retain CO2.
Electrolyte link: In acidosis, H+ shifts into cells and K+ tends to move out → hyperkalemia risk. Alkalemia often trends toward hypokalemia and lower ionized calcium, which can contribute to neuromuscular irritability.
Objective 10

Develop and implement an NCP using the PERSON framework

Course sourceLecturePERSON framework from the provided NUR 121 Assessment Guide; oxygen lectures provide disease-specific interpretation/interventions.
How to use PERSON: It is a whole-person assessment guide, not six mandatory nursing diagnoses. For respiratory patients, the O domain usually contains the most immediate airway/breathing data. Use other domains only when they matter to the current patient.

Example: COPD exacerbation PERSON assessment

DomainRespiratory-relevant data
PAge; baseline LOC/orientation/cognition; emotional state/anxiety; coping; support system/living arrangement; teaching needs. New mental-status change can signal worsening oxygenation/ventilation.
EOnly when relevant: urine output for hydration/perfusion, vomiting/diarrhea causing fluid/electrolyte loss, constipation from meds/immobility, diaphoresis during significant respiratory distress.
RPain (especially pleuritic/chest pain); activity/ambulation; ADLs/activity tolerance; sleep/rest. Focus on fatigue, exertional dyspnea, and sleep disruption from cough/breathing difficulty.
SAllergies/reactions; fall risk/new confusion; sedative use; tobacco/drug/alcohol use; temperature; WBC; immunization status; IV-site status when IV therapy is present.
OBP; HR/rhythm; RR/character; SpO2; room air vs oxygen and L/min; pulses/cap refill; edema; skin color; lung sounds; cough/sputum; SOB/DOE; chest pain; relevant labs/x-ray. Core respiratory domain.
NDiet/% eaten; fluid I/O; height/weight/BMI; hydration/IV fluids; glucose/insulin when steroids matter; Na, K, Cl, CO2, BUN, creatinine, glucose when ordered.

Sample priority care plan

Care-plan elementExample
Nursing problemImpaired gas exchange related to ventilation-perfusion imbalance/airflow obstruction as evidenced by hypoxemia, dyspnea and abnormal ABG/SpO2.
Goal / outcomePatient maintains prescribed oxygenation target, shows reduced work of breathing, and stable/improving mental status and ABG trend.
InterventionsPosition upright; assess RR/effort/breath sounds/mental status; titrate oxygen only per order/protocol; administer bronchodilators; coach pursed-lip breathing; promote secretion clearance; obtain ABG/notify provider for worsening status; prepare NIV/escalation if indicated.
RationalesPositioning/bronchodilation improve ventilation; controlled oxygen treats hypoxemia; breathing techniques prolong exhalation; mental-status/ABG changes may reveal CO2 retention or impending failure.
EvaluationCompare with baseline and goal: SpO2/PaO2, PaCO2/pH, RR/effort, speech, dyspnea rating, breath sounds, activity tolerance.

Adapt the priority problem by disease

DiseaseLikely first respiratory problems
AsthmaIneffective breathing pattern / impaired gas exchange from acute bronchoconstriction; ineffective airway clearance when mucus is significant.
COPDImpaired gas exchange, ineffective airway clearance, activity intolerance, imbalanced nutrition and anxiety may coexist.
PneumoniaImpaired gas exchange + ineffective airway clearance related to inflammatory exudate/secretions; hyperthermia, pain and fluid deficits may also need care.
Objective 11

Develop and implement a teaching plan

LectureWeb supplementLecture: asthma action plan and inhalers; COPD promotion; pneumonia discharge teaching. Web updates vaccines/current asthma strategy.
PatientTeachHow to verify learning
COPDSmoking cessation; inhaler sequence/technique; pursed-lip and huff cough; oxygen fire safety; pacing/energy conservation; nutrition; vaccination; recognize exacerbation: increased dyspnea/sputum, fever, confusion, falling SpO2.Teach-back + return demonstration of inhaler/breathing technique; patient states when to call/seek emergency care.
AsthmaController vs reliever; action-plan zones; personal-best PEF; trigger reduction; spacer/MDI or DPI technique; rinse mouth after ICS; do not rely on SABA alone if current plan uses an ICS-containing reliever/controller.Patient calculates zones, demonstrates peak flow/inhaler, and explains red-zone response.
PneumoniaTake antibiotics exactly as prescribed if ordered; hydration/rest; cough/deep breathing and mobility; aspiration precautions if relevant; smoking cessation; hand hygiene; influenza/pneumococcal vaccination; warning signs.Patient states medication schedule, prevention steps, and when worsening dyspnea, confusion, persistent fever or dehydration requires care.
Teaching sequence: Assess readiness and baseline knowledge → choose one or two priority learning needs → teach in plain language → demonstrate → have the patient teach back/return-demonstrate → document response and reinforce.
Objective 12

Tasks that may be delegated to assistive personnel (AP)

Web supplementDelegation follows state law, patient stability, AP competency and facility policy. [W11]

May be appropriate for trained AP in a stable patient

  • Obtain routine vital signs and pulse oximetry; report values outside specified limits.
  • Assist with positioning, hygiene, oral care, meals, ambulation, and directed activity.
  • Measure intake/output and weight; collect routine sputum/urine specimen when trained.
  • Reinforce already-taught basic mobility/comfort routines within role and report intolerance.
  • Immediately report dyspnea, cyanosis, new confusion, chest pain, abnormal RR/SpO2, or inability to perform usual activity.

RN responsibilities - do not delegate

  • Initial/focused respiratory assessment and interpretation of abnormal data.
  • Titrating oxygen based on clinical judgment or changing respiratory therapy outside delegated/order parameters.
  • Interpreting ABGs, pulse-ox trends, or PFTs; diagnosing deterioration.
  • Initial teaching, asthma/COPD action-plan education, inhaler teaching/evaluation, care-plan development/evaluation.
  • Assessment of unstable patients, triage, prioritization, or deciding whether rapid response/provider notification is required.
Five-rights mindset: Right task, right circumstance, right person, right directions/communication, right supervision/evaluation. The RN remains accountable for the delegation decision and patient evaluation.
Objective 13

Prioritization: situations requiring immediate nursing intervention

LectureWeb supplementLecture danger signs: status asthmaticus, hypoxemia, respiratory failure, sepsis; web adds priority framing.
Situation / red flagWhy it is dangerousImmediate nursing priority
Asthma: silent chest, unable to speak full sentences, exhaustion, falling LOC, quick-relief med not helpingMinimal airflow / impending respiratory arrest.ABCs, high-Fowler if tolerated, oxygen, rapid response/emergency help, bronchodilator treatment, prepare ventilation.
Any patient: severe hypoxemia, cyanosis with distress, RR rapidly worsening, new confusion or somnolenceBrain/heart may be under-oxygenated; hypercapnia may also depress consciousness.Assess airway/ventilation, verify pulse-ox signal/device, apply/titrate ordered oxygen, call urgent help, ABG/ventilatory support as indicated.
COPD: increasing drowsiness + rising PaCO2 / falling pHAcute-on-chronic ventilatory failure.Notify/rapid response based on severity; support ventilation, bronchodilators, controlled oxygen, prepare NIV/intubation.
Pneumonia: hypotension, tachycardia, altered mentation, low urine output, escalating oxygen needSepsis/shock or respiratory failure.Sepsis/rapid-response pathway: oxygenation, IV access/labs/cultures, antibiotics/fluids as ordered, perfusion reassessment.
Sudden unilateral severe dyspnea/pleuritic pain + markedly decreased breath soundsPossible pneumothorax; tension physiology can obstruct circulation.Emergency assessment and provider/rapid response; oxygen/support; prepare decompression/chest-tube care if ordered.
New stridorUpper-airway narrowing.Airway emergency: summon help, support oxygenation, prepare advanced-airway treatment.
Non-rebreather reservoir collapses or oxygen supply disconnectsHigh-concentration device is no longer functioning; suffocation risk with one-way valves.Restore oxygen flow immediately, assess patient/SpO2, replace equipment as needed.
NCLEX priority rule: When choices compete, address airway and ventilation first, then oxygenation and circulation. Teaching, nutrition, and routine specimen collection wait when the patient is unstable.
Objective 14

Define and use required terms A-R

LectureWeb supplementLecture definitions are preserved; web material completes clinical use and safety nuances.
AVentilation-perfusion (V/Q) scanning

Nuclear-medicine comparison of air reaching lung regions (V) with blood reaching them (Q). A mismatch can support pulmonary embolism evaluation.

B1FEV1

Forced expiratory volume in the first second of a forced exhalation. Used to quantify airflow obstruction and grade COPD airflow limitation.

B2FVC

Forced vital capacity: total volume forcefully exhaled after a full inspiration. The FEV1/FVC ratio expresses how much exits in the first second.

CPulse oximetry

Noninvasive estimate of SpO2. Does not measure PaCO2 or ventilation. Poor perfusion, motion, cold skin, nail products and device bias can affect accuracy; confirm unexpected values clinically/with ABG when needed.

DAtopy

Genetic tendency to develop IgE-mediated allergic responses; lecture links atopy with allergic asthma.

EIgE and eosinophilic blood levels

Biomarkers that may support allergic/Type 2 asthma phenotyping. Elevated values support the pattern; normal values do not exclude asthma.

FAlpha-1 antitrypsin (AAT)

Protective antiprotease made mainly by the liver. Inherited deficiency can damage lungs/liver and is a COPD risk factor, especially emphysema.

GPursed-lip breathing

Inhale gently through nose, exhale slowly through partially closed lips. Prolongs exhalation, reduces dynamic airway collapse/air trapping, slows RR, and can reduce dyspnea in COPD.

HHuff coughing

Airway-clearance technique using a medium/deep breath followed by forceful open-glottis exhalation (“huff”) to move mucus with less airway collapse than repeated hard coughing.

IPeak flow meter

Handheld device measuring peak expiratory flow (PEF). Asthma plans compare today's value with personal best.

JCPAP

Continuous positive airway pressure: one set positive pressure through the respiratory cycle in a spontaneously breathing patient. Helps splint airways/alveoli open and improve oxygenation.

KBiPAP

Bilevel positive airway pressure: higher inspiratory pressure and lower expiratory pressure. Provides ventilatory assistance plus airway/alveolar splinting.

LAllen test

Bedside collateral-circulation assessment before radial arterial puncture in settings where facility policy requires it; lecture places it before ABG draw.

MRespiratory acidosis

Primary CO2 retention/hypoventilation: pH <7.35 with PaCO2 >45 before/without full compensation.

NRespiratory alkalosis

Primary excessive CO2 loss/hyperventilation: pH >7.45 with PaCO2 <35 before/without full compensation.

OMetabolic acidosis

Primary bicarbonate deficit or acid gain: pH <7.35 with HCO3 <22 before/without full compensation.

PMetabolic alkalosis

Primary bicarbonate excess or hydrogen loss: pH >7.45 with HCO3 >26 before/without full compensation.

QPartial compensation

The other system is responding, so PaCO2 and HCO3 are both abnormal, but pH is still outside 7.35-7.45.

RFull compensation

Nursing-exam shorthand: pH has returned to 7.35-7.45 while PaCO2 and HCO3 remain abnormal. Determine primary disorder from direction/pattern and clinical context.

Asthma action-plan zones: Green = 80-100% personal-best PEF. Yellow = 50-79%. Red = <50%. Symptoms matter too; severe dyspnea with poor response to rescue medication is an emergency even before a meter is used.
Objective 15

Interdisciplinary collaboration

LectureWeb supplementLecture specifically describes pulmonary rehab as multidisciplinary; web completes team roles.
Team memberRole in COPD / asthma / pneumonia care
Primary provider / hospitalistCoordinates diagnosis, treatment, escalation and discharge plan.
PulmonologistComplex COPD/asthma, recurrent exacerbations, advanced testing, bronchoscopy, NIV/ventilation planning, lung-reduction/transplant evaluation.
Respiratory therapistOxygen devices, nebulizers/inhalers, airway-clearance therapies, NIV/ventilator management, respiratory teaching.
PharmacistInhaler selection/technique, interaction review, theophylline safety, steroid/bronchodilator optimization, smoking-cessation pharmacotherapy.
DietitianCOPD weight loss/cachexia or obesity, nutrient-dense small meals, hydration and individualized calorie/protein goals.
PT / OT / pulmonary rehabConditioning, exercise tolerance, energy conservation, ADLs and functional recovery.
Speech-language pathologistSwallow evaluation and aspiration-prevention plan when dysphagia is suspected.
Infectious disease / microbiologySevere, resistant, opportunistic or complicated pneumonia; antimicrobial stewardship and culture interpretation.
Case management / social workHome oxygen/equipment, insurance/med access, transportation, rehabilitation, smoking-cessation/community resources.
Palliative care / hospiceDyspnea/symptom management, goals-of-care discussion, advance-care planning, caregiver support in advanced disease.
Objective 16

Medication and vaccine profiles

LectureWeb supplementCurrent practiceLecture: L2 pp. 15-26, 41-44; L1 pp. 38-39. Web medication safety: [W12-W25]; vaccine update: [W6-W7].
RESCUE: albuterol / levalbuterol (SABA)CONTROLLER: ICS, LABA regimens, LAMA, leukotrienes, biologics
Rescue vs controller anchor: Albuterol/levalbuterol rapidly relieve bronchospasm. ICS and other maintenance therapies control disease over time. Never substitute a controller for emergency rescue unless the patient’s current asthma plan specifically uses an ICS-formoterol reliever.
16A. Beta2-adrenergic agonists - albuterol, levalbuterol, salmeterol
Classification
SABA: albuterol/levalbuterol. LABA: salmeterol.
Action
Stimulate beta2 receptors → relax bronchial smooth muscle → bronchodilation.
Indications
SABA: rapid relief/prevention of bronchospasm. Salmeterol: maintenance in COPD and asthma as part of an appropriate controller regimen; not acute rescue.
Routes
Inhaled MDI/nebulized albuterol/levalbuterol; salmeterol inhaled dry powder.
Adverse effects
Tremor, nervousness, headache, tachycardia/palpitations; paradoxical bronchospasm is serious. Excess beta-agonist exposure can contribute to hypokalemia.
Nursing / teaching
Assess breath sounds/RR/HR and response. Frequent rescue use or poor response signals worsening disease. LABA is not asthma monotherapy and not rescue. [W12-W14]
16B. Xanthine derivative - theophylline (Uniphyl, Theodur)
Classification
Methylxanthine bronchodilator.
Action
Produces bronchodilation and can increase respiratory drive; lecture notes adenosine-receptor blockade.
Indications
Alternative/add-on therapy in selected asthma/COPD patients; not acute rescue.
Route
Oral immediate/extended-release formulations.
Adverse effects
Nausea/vomiting, insomnia, tremor, tachyarrhythmias; severe toxicity can cause seizures and dangerous arrhythmias.
Nursing / teaching
Narrow therapeutic index. Monitor ordered serum levels and interactions. Smoking changes clearance; caffeine and many drugs can increase adverse effects. Report vomiting, marked tachycardia, or neurologic symptoms. [W15]
16C. Anticholinergics - ipratropium (Atrovent), tiotropium (Spiriva)
Classification
Ipratropium = SAMA; tiotropium = LAMA.
Action
Block muscarinic acetylcholine receptors → reduce bronchoconstriction and mucus secretion.
Indications
COPD bronchodilation; ipratropium also used with SABA in severe asthma exacerbation. Tiotropium is maintenance, not rescue.
Route
Inhaled aerosol/nebulized ipratropium; tiotropium inhalation device.
Adverse effects
Dry mouth; blurred vision/eye symptoms if medication contacts eyes; urinary retention can occur.
Nursing / teaching
Teach device-specific technique. Do not swallow tiotropium inhalation capsules. Assess response and anticholinergic effects. [W16-W17]
16D. Corticosteroids - fluticasone (Flovent), budesonide (Pulmicort)
Classification
Inhaled corticosteroids (ICS).
Action
Suppress airway inflammation and hyperresponsiveness.
Indications
Daily controller therapy for persistent asthma; selected COPD patients/combination regimens. Not acute rescue.
Route
Inhaled powder/aerosol/nebulized formulations depending product.
Adverse effects
Oral candidiasis, dysphonia/hoarseness, throat irritation; systemic effects are more likely with high/prolonged exposure.
Nursing / teaching
Use consistently. Rinse mouth and spit after dose. Spacer may reduce oropharyngeal deposition with compatible MDI. [W18-W19]
16E. Leukotriene receptor modifier - montelukast (Singulair)
Classification
Leukotriene receptor antagonist (LTRA).
Action
Blocks leukotriene receptors → reduces leukotriene-mediated bronchoconstriction/inflammation.
Indications
Asthma prevention/control, exercise-induced bronchospasm prevention, selected allergic rhinitis. Not acute rescue.
Route
Oral tablet/chewable/granules.
Adverse effects
Headache/GI effects; serious neuropsychiatric reactions can occur, including mood/behavior changes and suicidal thoughts/actions.
Nursing / teaching
Teach patient/family to report new neuropsychiatric symptoms promptly. Continue rescue plan for acute symptoms. [W20]
16F. Leukotriene synthesis inhibitor - zileuton (Zyflo)
Classification
5-lipoxygenase inhibitor / leukotriene synthesis inhibitor.
Action
Inhibits leukotriene synthesis → decreases inflammatory bronchoconstrictor effects.
Indications
Alternative controller for persistent asthma; not acute rescue.
Route
Oral.
Adverse effects
Elevated liver enzymes/hepatotoxicity risk; GI upset/headache and drug interactions.
Nursing / teaching
Lecture: monitor liver function tests. Review interactions and symptoms of liver injury; use only as prescribed. [W21]
16G. Anti-IgE - omalizumab (Xolair)
Classification
Anti-IgE monoclonal antibody / biologic.
Action
Binds IgE and decreases allergic inflammatory signaling.
Indications
Selected allergic asthma not adequately controlled with standard therapy; other FDA indications also exist.
Route
Subcutaneous injection, commonly every 2 or 4 weeks depending regimen.
Adverse effects
Injection-site reactions, headache; serious anaphylaxis can occur.
Nursing / teaching
Administer/observe according to product protocol; be prepared to treat anaphylaxis. It is not a rescue drug for acute bronchospasm. [W22]
16H. Nicotine supplement - NicoDerm CQ
Classification
Nicotine replacement therapy.
Action
Provides controlled nicotine to reduce withdrawal/cravings while smoking is stopped.
Indications
Smoking cessation.
Route
Transdermal patch, typically applied daily per product regimen.
Adverse effects
Local skin irritation, dizziness, headache, nausea/vomiting, sleep disturbance/vivid dreams; abnormal rhythm can be serious.
Nursing / teaching
Do not smoke or use extra nicotine while using the patch unless specifically directed by a cessation clinician because overdose can occur. Rotate sites; fold used patches sticky sides together and keep away from children/pets. [W23]
16I. Antitussive - dextromethorphan (Robitussin products)
Classification
Antitussive.
Action
Decreases activity of the medullary cough center to suppress cough.
Indications
Temporary relief of nonproductive/troublesome cough when suppression is appropriate.
Route
Oral liquids/capsules/lozenges/extended-release formulations.
Adverse effects
Dizziness, drowsiness, nausea/GI upset; misuse can cause serious toxicity.
Nursing / teaching
Current classification is antitussive, not expectorant. Avoid routinely suppressing a productive cough needed to clear secretions without provider guidance. Check combination products and MAOI interactions. [W24]
16J. Expectorant - guaifenesin (Mucinex)
Classification
Expectorant.
Action
Thins airway mucus, making secretions easier to cough up.
Indications
Chest congestion with thick secretions.
Route
Oral immediate- or extended-release forms.
Adverse effects
Usually mild; nausea, vomiting, dizziness/headache may occur.
Nursing / teaching
Encourage adequate fluids if not contraindicated. Do not crush extended-release tablets. It relieves symptoms but does not treat the infection/cause. [W25]
16K. Analgesic/antipyretic - acetaminophen (Tylenol)
Classification
Non-opioid analgesic / antipyretic.
Action
Reduces pain perception and fever.
Indications
Fever, headache, pleuritic discomfort/mild-moderate pain in pneumonia/bronchitis when appropriate.
Routes
Oral; rectal and IV formulations also exist.
Adverse effects
Dose-related hepatotoxicity can be severe/fatal; serious skin or hypersensitivity reactions are uncommon.
Nursing / teaching
Count acetaminophen from all combination products and follow label/provider maximum. Use extra caution with liver disease or heavy alcohol use. [W25A]
16L. Vaccines - influenza and pneumococcal
Classification
Active immunization / vaccines.
Action
Stimulate adaptive immunity to reduce infection and severe disease risk.
Indications
Influenza: annual vaccination for nearly everyone ≥6 months unless contraindicated. Pneumococcal: age- and risk-based adult vaccination.
Routes
Most influenza vaccines are IM; an intranasal live-attenuated option exists for eligible people. PCVs are IM; PPSV23 may be IM or subcutaneous per product labeling.
Adverse effects
Local soreness, fatigue/low-grade systemic symptoms; severe allergic reaction is rare.
Nursing / teaching
Verify age, history, prior doses and contraindications. Lecture lists Pneumovax 23. Current CDC: adults who need pneumococcal vaccine may receive PCV20/PCV21 alone or PCV15 followed by PPSV23, depending on history/risk. Do not use PPSV23-only as the universal current schedule. [W6-W7]
Rapid Review

ATI / NCLEX-style differentiation

LectureWeb supplementCurrent practiceExam-focused synthesis from the completed guide.
ConditionCore patternHallmark cluePriority / treatment focus
AsthmaVariable/reversible airway obstructionWheeze + prolonged expiration; trigger pattern; PEF zones. Silent chest = severe.SABA/acute bronchodilation + oxygen; anti-inflammatory controller; action plan.
Chronic bronchitisCOPD airway inflammation + mucusChronic productive cough/sputum, coarse sounds.Smoking cessation, bronchodilators, airway clearance, rehab, oxygen if prescribed.
EmphysemaCOPD alveolar destruction + loss of recoilAir trapping/hyperinflation, barrel chest, diminished sounds.Prolong exhalation/pursed lips, bronchodilators, rehab; selected surgery.
PneumoniaInfectious alveolar inflammation/exudateFever/chills + sputum + crackles/pleuritic pain + infiltrate.Oxygenation, timely antimicrobials when indicated, hydration/airway clearance, sepsis surveillance.
COPD exacerbationAcute worsening dyspnea/sputum ± infectionMental-status change, worsening ABG, hypercapnia/respiratory acidosis.Controlled oxygen + bronchodilators + trigger treatment; NIV/ventilation if failing.
Acute bronchitisAcute bronchial inflammationProductive cough; low-grade fever/malaise; often self-limited.Supportive care, fluids/rest, symptom control; lecture: usually no antibiotics.
Respiratory acidosispH down, PaCO2 upHypoventilation / CO2 retention.Improve ventilation and treat cause; renal HCO3 compensation if chronic.
Respiratory alkalosispH up, PaCO2 downHyperventilation, tingling/lightheadedness.Treat cause of hyperventilation.
Metabolic acidosispH down, HCO3 downDKA/renal failure/diarrhea; Kussmaul.Treat cause; lungs lower CO2.
Metabolic alkalosispH up, HCO3 upVomiting/NG suction/diuretics; hypokalemia.Correct cause/volume-electrolytes as ordered; lungs retain CO2.
1) Silent chestEmergency: minimal airflow / impending respiratory arrest.
2) COPD diagnosisPost-bronchodilator FEV1/FVC <0.70.
3) Rescue vs controllerSABA is rapid rescue; ICS is an anti-inflammatory controller.
4) Pneumonia deteriorationCan progress to sepsis, ARDS, and respiratory failure.
5) ABG orderpH → PaCO2 → HCO3 → compensation → PaO2.
Priority frameAirway/ventilation → oxygenation → circulation → teaching.
Safety Notes

Course slide vs current practice

LectureCurrent practiceStudy the lecture wording for course questions; use updated guidance for real clinical care.
Lecture / course pointCurrent-practice clarification
COPD: FEV1/FVC <70% diagnosticUse post-bronchodilator FEV1/FVC <0.70 to confirm COPD. FEV1 grade alone does not determine all modern treatment decisions. [W1]
COPD: “hypoxic drive”Do not withhold needed oxygen. In acute COPD with hypercapnia risk, titrate to the ordered controlled target and reassess ventilation/ABG.
Asthma: SABA is rescue medicationCorrect for rapid bronchodilation, but current GINA recommends an ICS-containing treatment strategy and recommends against SABA-only treatment for adults/adolescents. [W2]
Pneumonia types include HCAPKnow for lecture questions, but modern ATS/IDSA guidelines removed HCAP as a separate category. [W4]
Pneumonia prevention: Pneumovax 23Know the lecture example, but current CDC adult pneumococcal schedules include PCV15/20/21 with PPSV23 used in selected sequences. [W6]
Pulse ox as oxygen measureUseful screening, but confirm unexpected/critical values and assess the patient. ABG provides PaO2/PaCO2; pulse ox does not measure CO2. [W9-W10]
Lecture Extension

Acute bronchitis and inhaler/device technique

LectureWeb supplementAcute bronchitis is in Part 2 and the required-resource list even though it is not a numbered disease objective.

Acute bronchitis

  • Inflammation of the bronchi. Lecture primary symptom: productive cough; low-grade fever, headache, malaise, and exertional SOB can occur.
  • Lecture treatment is supportive: fluids, rest, anti-inflammatory agents, cough suppressants/bronchodilators as appropriate. Usually no antibiotics.
  • Escalate assessment for fever, hypoxemia, focal findings, severe dyspnea, hemoptysis, frailty, or persistent/worsening symptoms suggesting pneumonia or another diagnosis.

Inhaler memory

MDI = slow inhalation.

DPI = quick/deep inhalation.

ICS = rinse and spit after.

Controller ≠ rescue.

DeviceHigh-yield technique
MDIShake/prime as product directs; exhale; seal lips; press canister while inhaling slowly and deeply; hold breath about 10 sec if able; wait between puffs as directed. Spacer improves coordination for compatible MDIs.
DPILoad dose; exhale away from device; seal lips; inhale quickly and deeply; hold breath; do not blow moisture into device. No spacer.
NebulizerPlace prescribed solution in cup, connect to flow/compressor, sit upright, breathe slowly/deeply through mouthpiece/mask until mist stops; clean equipment per instructions.
ICS aftercareRinse mouth and spit after inhaled corticosteroid to reduce thrush/hoarseness risk.
Coverage Verification

Coverage audit from the completed study guide

Numbered objectives16 / 16 addressed.
Objective 14 terms18 / 18 required terms, plus FEV1 and FVC subterms.
Objective 16 meds/vaccines12 / 12 classifications with named examples.
PERSON frameworkMatched to the provided NUR 121 PERSON Assessment Guide; respiratory-relevant items only.
Primary sourceOxygenation Lecture Parts 1 and 2 are cited throughout as L1/L2.
Current-practice flagsPost-bronchodilator spirometry, asthma SABA-only strategy, HCAP terminology, “hypoxic drive,” and pneumococcal schedule.
Study order: First memorize the Rapid Differentiation table and ABG algorithm. Then practice priority questions: silent chest/respiratory failure, sepsis, acute CO2 retention, oxygen-device failure, and rescue-vs-controller medications. Finish with the medication tables and current-practice corrections.
Sources

References and web supplement sources

Primary course source: Kuhn, K., MSN, RN. Interference with the Intake of Oxygen - Part 1. County College of Morris course lecture PDF, provided by the student. (L1)

Primary course source: Kuhn, K., MSN, RN. Interference with the Intake of Oxygen - Part 2. County College of Morris course lecture PDF, provided by the student. (L2)

Primary course source: Unit 7 Oxygenation Study Guide - Health Need: Oxygen; Health Problem: Interference with the Intake of Oxygen. Course objective sheet, provided by the student.

Course source: County College of Morris. NUR 121 - Fundamentals of Nursing PERSON Assessment Guide. Used for Objective 10 only.

W1. GOLD. 2026 GOLD Report and Pocket Guide. https://goldcopd.org/2026-gold-report-and-pocket-guide/

W2. GINA. 2026 GINA Strategy Report. https://ginasthma.org/wp-content/uploads/2026/05/GINA-2026-Strategy-Report-WMS.pdf

W3. ATS/IDSA. Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. https://www.idsociety.org/practice-guideline/community-acquired-pneumonia-cap-in-adults/

W4. ATS/IDSA. Hospital-Acquired and Ventilator-Associated Pneumonia Guideline. https://www.idsociety.org/practice-guideline/hap_vap/

W5. CDC. Pneumonia Risk Factors. https://www.cdc.gov/pneumonia/risk-factors/index.html

W6. CDC. Pneumococcal Vaccine Recommendations, updated February 2026. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html

W7. CDC. 2026-2027 Flu Season / annual influenza vaccination guidance. https://www.cdc.gov/flu/season/2026-2027.html

W8. Merck Manual Professional. Acid-Base Disorders and compensation tables. https://www.merckmanuals.com/professional/nephrology/acid-base-regulation-and-disorders/acid-base-disorders

W9. MedlinePlus. Arterial Blood Gas (ABG) Test. https://medlineplus.gov/lab-tests/arterial-blood-gas-abg-test/

W10. MedlinePlus. Pulse Oximetry. https://medlineplus.gov/lab-tests/pulse-oximetry/

W11. NCSBN. Delegation / National Guidelines for Nursing Delegation. https://www.ncsbn.org/nursing-regulation/practice/delegation.page

W12. MedlinePlus. Albuterol Oral Inhalation. https://medlineplus.gov/druginfo/meds/a682145.html

W13. MedlinePlus. Levalbuterol Oral Inhalation. https://medlineplus.gov/druginfo/meds/a603025.html

W14. MedlinePlus. Salmeterol Oral Inhalation. https://medlineplus.gov/druginfo/meds/a695001.html

W15. MedlinePlus. Theophylline. https://medlineplus.gov/druginfo/meds/a681006.html

W16. MedlinePlus. Ipratropium Oral Inhalation. https://medlineplus.gov/druginfo/meds/a695021.html

W17. MedlinePlus. Tiotropium Oral Inhalation. https://medlineplus.gov/druginfo/meds/a604018.html

W18. MedlinePlus. Fluticasone Oral Inhalation. https://medlineplus.gov/druginfo/meds/a601056.html

W19. MedlinePlus. Budesonide Oral Inhalation. https://medlineplus.gov/druginfo/meds/a699056.html

W20. MedlinePlus. Montelukast. https://medlineplus.gov/druginfo/meds/a600014.html

W21. MedlinePlus. Zileuton. https://medlineplus.gov/druginfo/meds/a697013.html

W22. MedlinePlus. Omalizumab Injection. https://medlineplus.gov/druginfo/meds/a603031.html

W23. MedlinePlus. Nicotine Transdermal Patch. https://medlineplus.gov/druginfo/meds/a601084.html

W24. MedlinePlus. Dextromethorphan. https://medlineplus.gov/druginfo/meds/a682492.html

W25. MedlinePlus. Guaifenesin. https://medlineplus.gov/druginfo/meds/a682494.html

W25A. MedlinePlus. Acetaminophen. https://medlineplus.gov/druginfo/meds/a681004.html

W26. NCBI Bookshelf, Nursing Skills. Chapter 11: Oxygen Therapy / oxygen-device settings. https://www.ncbi.nlm.nih.gov/books/NBK596733/

Final exam strategy: Know what makes each disease different, what makes the patient unstable, and which intervention changes oxygenation/ventilation first. Memorize medication classes by rescue vs controller and learn ABGs as a repeatable algorithm rather than isolated numbers.
↑ Back to top